Kohjin Bio Co., Ltd. Share Price

Equities

177A

JP3283630006

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 19/07/2024 am IST 5-day change 1st Jan Change
2,450 JPY -7.55% Intraday chart for Kohjin Bio Co., Ltd. +22.50% 0.00%

Financials

Sales 2025 * 4.72B 29.93M 2.51B Sales 2026 * 5.13B 32.55M 2.73B Capitalization 12.29B 77.96M 6.53B
Net income 2025 * 618M 3.92M 328M Net income 2026 * 671M 4.26M 357M EV / Sales 2025 * 2.6 x
Net cash position 2025 * - 0 0 Net cash position 2026 * - 0 0 EV / Sales 2026 * 2.4 x
P/E ratio 2025 *
19.7 x
P/E ratio 2026 *
18.3 x
Employees 159
Yield 2025 *
0.57%
Yield 2026 *
0.57%
Free-Float 27.87%
More Fundamentals * Estimated data
Dynamic Chart
1 day-7.55%
1 week+22.50%
Current month+26.42%
1 month+41.21%
More quotes
1 week
1 987.00
Extreme 1987
3 065.00
1 month
1 800.00
Extreme 1800
3 065.00
Current year
1 466.00
Extreme 1466
3 065.00
1 year
1 466.00
Extreme 1466
3 065.00
3 years
1 466.00
Extreme 1466
3 065.00
5 years
1 466.00
Extreme 1466
3 065.00
10 years
1 466.00
Extreme 1466
3 065.00
More quotes
Date Price Change Volume
19/24/19 2,450 -7.55% 1,642,700
18/24/18 2,650 -5.73% 3,666,300
17/24/17 2,811 +21.64% 2,041,400
16/24/16 2,311 +15.55% 1,380,900
12/24/12 2,000 +4.06% 72,100

Delayed Quote Japan Exchange, July 19, 2024 at 11:30 am IST

More quotes
Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The Company operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.
More about the company

Annual profits - Rate of surprise